Spyre Therapeutics (SYRE) Debt to Equity (2023 - 2025)
Spyre Therapeutics' Debt to Equity history spans 3 years, with the latest figure at $0.03 for Q4 2025.
- For Q4 2025, Debt to Equity fell 34.13% year-over-year to $0.03; the TTM value through Dec 2025 reached $0.03, down 34.13%, while the annual FY2025 figure was $0.03, 34.13% down from the prior year.
- Debt to Equity reached $0.03 in Q4 2025 per SYRE's latest filing, up from $0.02 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.13 in Q2 2025 to a low of -$0.79 in Q2 2023.
- Average Debt to Equity over 3 years is -$0.04, with a median of $0.02 recorded in 2025.
- The largest YoY upside for Debt to Equity was 1763.77% in 2025 against a maximum downside of 67.96% in 2025.
- A 3-year view of Debt to Equity shows it stood at $0.01 in 2023, then soared by 541.21% to $0.05 in 2024, then tumbled by 34.13% to $0.03 in 2025.
- Per Business Quant, the three most recent readings for SYRE's Debt to Equity are $0.03 (Q4 2025), $0.02 (Q3 2025), and $0.13 (Q2 2025).